McKesson price target lowered to $1,000 from $1,040 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on McKesson (MCK) to $1,000 from $1,040 and keeps a Buy rating on the shares. The swift decline of cash-pay GLP-1 prices is driving a shift of scripts away from insurance and the rapid growth of cash-pay scripts for Wegovy and Zepbound could cause McKesson’s FY27 EBIT guidance in the Prescription Technology Solutions segment to fall short of Street expectations, the analyst tells investors.